Regenerative medicine company Orthocell (ASX:OCC) says commercialisation of its flagship nerve repair product Remplir in the US is progressing on plan, with early clinical use and steps to secure broader hospital adoption underway.
Latest Video
New Stories
-
New Zealand risks losing $763 million clinical trials sector as other countries step up
November 19, 2026 - -
A tale of two government programs - one held flat and the other still running hot
November 19, 2026 - - Latest News -
Immutep goes back to smaller batch efti after review finds glycan differences in failed trial drug
November 18, 2026 - - Australian Biotech -
Genetic Signatures walks away from Microba merger after funding shortfall
November 18, 2026 - - Australian Biotech -
The TGA's new guidance risks blurring the line between advertising and journalism
November 18, 2026 - - Latest News -
Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
November 18, 2026 - - Latest News -
Hungary's Gedeon Richter offers $604 million for Mayne Pharma
November 18, 2026 - - Latest News

